GAD Drug Development Has Stalled for 16 Years. iNGENu CRO Is Building the Trial Framework to Change That.
The FDA has not approved a new generalized anxiety disorder treatment since 2009. With a high placebo effect, complex neurobiology, and a long list of failed candidates, GAD represents one of psychiatry's most persistent clinical challenges. Here is what the data shows, and how precision trial design is finally shifting…
Medical Daily ·